Article
Multidisciplinary Sciences
Priya K. Dharshini, Ramya D. Devi, S. Banudevi, Vedha Hari B. Narayanan
Summary: By using spray drying technology, chitosan nanoparticles were successfully developed to enhance the solubility and bioavailability of dolutegravir (DTG). The nanoparticles showed a significant increase in C-max and improved bioavailability compared to pure DTG. This study demonstrates the potential of chitosan-based nanoparticles as carriers for oral administration of DTG in pediatric HIV patients.
SCIENTIFIC REPORTS
(2022)
Article
Infectious Diseases
Benjamin M. Wenk, Herbert A. Mbunkah, Ndi N. Nsanwe, Eyongetah T. Mbu, Lydia M. Besong, Bella A. Sama, Emmanuel Orock, Christine Leemann, Karin J. Metzner
Summary: This study investigated the prevalence of pretreatment HIV-1 resistance to INSTIs in Cameroon and found a low resistance rate. However, a majority of individuals carried polymorphic accessory INSTI drug resistance mutations, which may require further studies to assess their impact on INSTI-based ART regimens.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2021)
Article
Immunology
Murat Sayan, Figen Sarigul Yildirim, Sila Akhan, Ilkay Karaoglan, Halis Akalin
Summary: This study evaluated the mutations associated with INSTI resistance in naive HIV-1 infected patients. The results showed that INSTI resistance was not detected in patients who had not received antiretroviral treatment. However, a significant proportion of patients who had received INSTI treatment showed INSTI resistance mutations. The prevalence of drug resistance mutations varied among different drug classes.
CURRENT HIV RESEARCH
(2022)
Article
Medicine, General & Internal
Jesus Enrique Patino Escarcina, Eduardo Martins Netto, Carlos Brites
Summary: This study evaluated the efficacy, tolerability, and adverse events of Raltegravir and other third-line drugs as salvage regimens in real-life clinical settings. The results showed comparable survival rates and virologic suppression rates between Raltegravir and other drugs, suggesting that Raltegravir may be a viable option for salvage therapy.
Article
Infectious Diseases
Barbara Rossetti, Massimiliano Fabbiani, Domenico Di Carlo, Francesca Incardona, Ana Abecasis, Perpetua Gomes, Anna Maria Geretti, Carole Seguin-Devaux, Federico Garcia, Rolf Kaiser, Sara Modica, Adrian Shallvari, Anders Sonnerborg, Maurizio Zazzi
Summary: This study aims to explore the effectiveness and durability of INSTI-based regimens in pre-treated subjects. The results showed that both virological failure and INSTI discontinuation occur at substantial rates in viraemic subjects, highlighting the importance of INSTI resistance testing after treatment failure.
Article
Microbiology
Mark Underwood, Joe Horton, Keith Nangle, Judy Hopking, Kimberly Smith, Michael Aboud, Brian Wynne, Jorg Sievers, Eugene L. Stewart, Ruolan Wang
Summary: In the phase IIIb DAWNING study, treatment-experienced adults who received dolutegravir showed emergence of treatment-emergent INSTI resistance-associated substitutions, with some participants developing mutations like G118R and R263K. These mutations were associated with a significant increase in dolutegravir resistance compared to baseline levels. Overall, the study highlights the complex pathway to dolutegravir resistance involving HIV-1 phenotypic changes and reduced viral fitness.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Infectious Diseases
Roberta Gagliardini, Nicola Gianotti, Franco Maggiolo, Alessandro Cozzi-Lepri, Andrea Antinori, Silvia Nozza, Giuseppe Lapadula, Andrea De Luca, Cristina Mussini, Andrea Gori, Annalisa Saracino, Massimo Andreoni, Antonella d'Arminio Monforte, I. C. O. N. A. Foundation Study Group
Summary: This study aimed to compare the durability of treatment with rilpivirine-based and integrase strand transfer inhibitors-based first-line regimens in ART-naive HIV-infected individuals. The results showed a lower risk of treatment failure with RPV-based regimens compared to INSTIs-based regimens, especially when compared to DTG.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2021)
Article
Immunology
Patricia Pacheco, Nuno Marques, Paulo Rodrigues, Kamal Mansinho, Fernando Maltez, Nuno Janeiro, Claudia Franco, Diva Trigo, Joana Batista, Luis Duque, Maria Joao Lopes, Maria Joao Aleixo, Ana Rita Silva, Raquel Tavares, Joao Alves, Susana Peres, Diana Povoas, Sara Lino, Perpetua Gomes, Vania Araujo, Cristina Lopes
Summary: This study conducted in Portugal evaluated the safety and efficacy of triple therapy with dolutegravir plus 2 nucleoside reverse transcriptase inhibitors in treatment-naive PWHIV-2. The results showed that DTG combined with 2 NRTIs is a safe and effective first-line treatment for PWHIV-2, with a tolerability profile previously known.
CLINICAL INFECTIOUS DISEASES
(2023)
Review
Pharmacology & Pharmacy
Ke Zhang, Yang Zhang, Xinchao Liu, Aixin Li, Meixia Gao, Jianhua Hou, Chunxiang Guo, Tong Zhang, Hao Wu, Guanzhi Chen, Xiaojie Huang
Summary: This study conducted a network meta-analysis comparing the efficacy and safety of 3-drug regimens containing non-nucleoside reverse transcriptase inhibitor and integrase inhibitor in treatment-naive HIV-1-infected adults. The results showed that regimens containing integrase inhibitor, particularly dolutegravir, were generally superior to other regimens in terms of efficacy and safety outcomes.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Virology
Paraskevi C. Fragkou, Ignatios Ikonomidis, Dimitrios Benas, Dimitra Kavatha, Charalampos D. Moschopoulos, Konstantinos Protopapas, Gavriella Kostelli, John Thymis, Dionysia Mpirmpa, Irene Galani, Maria Tsakona, Chrysanthi Oikonomopoulou, George Theocharous, Vassilis G. Gorgoulis, Parisis Gallos, Sotirios Tsiodras, Anastasia Antoniadou, Antonios Papadopoulos, Helen Triantafyllidi
Summary: This study conducted a prospective cohort study on treatment-naive people living with HIV and found that the integrity of endothelial glycocalyx (EG) improved with antiretroviral treatment. This has important implications for the diagnosis and treatment of cardiovascular disease in people living with HIV.
Article
Infectious Diseases
Yu-Lin Lee, Kuan-Yin Lin, Shu-Hsing Cheng, Po-Liang Lu, Ning-Chi Wang, Mao-Wang Ho, Chia-Jui Yang, Bo-Huang Liou, Hung-Jen Tang, Shie-Shian Huang, Sung-Hsi Huang, Tun-Chieh Chen, Chi-Ying Lin, Shih-Ping Lin, Yuan-Ti Lee, Chien-Ching Hung
Summary: This retrospective study included 77 patients receiving dolutegravir plus boosted protease inhibitor treatment at 15 designated hospitals for HIV care in Taiwan. The study found that the two-drug regimen containing dolutegravir plus boosted protease inhibitor was effective for highly experienced HIV-positive patients. Virological response rate reached 85.7% at Week 48, but metabolic impact and weight gain should be closely monitored.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2021)
Article
Infectious Diseases
Zhenyan Wang, Min Zhang, Jiangrong Wang, Li Liu, Jun Chen, Renfang Zhang, Yang Tang, Yinzhong Shen, Tangkai Qi, Wei Song, Jianjun Sun, Shuibao Xu, Junyang Yang, Hongzhou Lu
Summary: This study evaluates the prevalence of HIV-1 mutation V179D/E and its impact on the virological response to the first-line efavirenz-based regimen in ART-naive patients in Shanghai, China. The study finds a high prevalence of V179D/E and suggests that the efavirenz-based regimen may not be suitable for patients with this mutation, especially those with a high baseline viral load.
INFECTIOUS DISEASES AND THERAPY
(2023)
Article
Immunology
Giovanni Guaraldi, Stefano Calza, Jovana Milic, Andrea Calcagno, Emanuele Foca, Matteo Rota, Stefano Renzetti, Anna Celotti, Matteo Siano, Benedetto Maurizio Celesia, Stefania Piconi, Giuseppe Vittorio de Socio, Anna Maria Cattelan, Giancarlo Orofino, Agostino Riva, Silvia Nozza, Giovanni di Perri
Summary: The study showed that switching to a dolutegravir-based regimen did not lead to significant weight gain in HIV patients aged 65 and older. Comparisons between different regimens and drug exposures also did not show significant differences in weight gain.
Article
Immunology
Zion Congrave-Wilson, Wesley A. Cheng, Yesun Lee, Stephanie Perez, Lauren Turner, Carolyn Jennifer Marentes Ruiz, Shirley Mendieta, Adam Skura, Jaycee Jumarang, Jennifer Del Valle, John Kubale, Emma Kaitlynn Allen, Paul G. Thomas, Aubree Gordon, Pia S. Pannaraj
Summary: This study compared the serological responses following natural infection and vaccination, finding that responses after natural infection were more variable while antibody levels after vaccination remained durable for up to 12 months. Individuals with both infection and vaccination had more robust and slower declining SARS-CoV-2-specific antibody levels.
Article
Immunology
Leonardo Calza, Marco Borderi, Vincenzo Colangeli, Fabio Esposito, Maddalena Giglia, Isabella Bon, Maria Carla Re
Summary: This study found that HIV-infected patients starting combination antiretroviral therapy (cART) may experience significant weight gain, but changes in body fat mass still require more clinical data support. However, in this study, it was observed that initiating antiretroviral treatment with either RAL plus tenofovir/emtricitabine or DRV/r led to comparable and non-significant increases in weight and body fat mass after 12 months.
AIDS RESEARCH AND HUMAN RETROVIRUSES
(2021)
Article
Public, Environmental & Occupational Health
Rishma Amarsy, Sandra Fournier, David Trystram, Catherine Monteil, Xavier Raynaud, Vincent Jarlier, Jerome Robert
Summary: The impact of COVID-19 pandemic on bloodstream infections due to Streptococcus pneumoniae and Streptococcus pyogenes was assessed in 25 university hospitals in Paris. The incidence rates of BSIs, which had been stable in 2018 and 2019, decreased for the two pathogens during the two lockdown periods in 2020. Containment policies such as social distancing, masking, and hand hygiene strengthening in community and hospital settings are likely to reduce BSIs caused by these pathogens.
AMERICAN JOURNAL OF INFECTION CONTROL
(2023)
Article
Infectious Diseases
Romain Palich, Sonia Burrel, Gentiane Monsel, Agathe Nouchi, Alexandre Bleibtreu, Sophie Seang, Vincent Berot, Cecile Brin, Ariane Gavaud, Yara Wakim, Nagisa Godefroy, Antoine Faycal, Yanis Tamzali, Thomas Grunemwald, Michel Ohayon, Eve Todesco, Valentin Leducq, Stephane Marot, Vincent Calvez, Anne-Genevieve Marcelin, Valerie Pourcher
Summary: This study describes the distribution of Monkeypox virus (MPXV) in the human body, and the results show that the virus is more frequently detected and has higher viral loads in the skin, anus, and throat. These findings suggest that transmission most likely occurs through direct body contact.
LANCET INFECTIOUS DISEASES
(2023)
Article
Immunology
Adolfo de Salazar, Laura Vinuela, Ana Fuentes, Elisa Teyssou, Charlotte Charpentier, Sidonie Lambert-Niclot, Esther Serrano-Conde, Marta Pingarilho, Lavinia Fabeni, Anne De Monte, Karl Stefic, Carlo Federico Perno, Antonio Aguilera, Iker Falces, Rafael Delgado, Sandra Fernandes, Isabel Diogo, Perpetua Gomes, Dimitrios Paraskevis, Maria-Mercedes Santoro, Francesca Ceccherini-Silberstein, Anne-Genevieve Marcelin, Federico Garcia
Summary: The prevalence of transmitted drug resistance to INSTIs and NRTIs and clinically relevant resistance was evaluated in newly diagnosed HIV patients naive to ART in Europe. The results showed low prevalence rates of INSTI-SDRMs (0.30%), NRTI-SDRMs (5.77%), INSTI-CRR (2.33%), and first-line NRTI-CRR (1.74-2.29%) during 2018-2021.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Infectious Diseases
Guillaume Martin-Blondel, Anne-Genevieve Marcelin, Cathia Soulie, Sofia Kaisaridi, Clovis Lusivika-Nzinga, Karen Zafilaza, Celine Dorival, Laura Nailler, Anais Boston, Anne-Marie Ronchetti, Clea Melenotte, Andre Cabie, Christophe Choquet, Albert Trinh-Duc, Karine Lacombe, Geraldine Gaube, Francois Coustilleres, Valerie Pourcher, Jean-Philippe Martellosio, Nathan Peiffer-Smadja, Marie Chauveau, Pierre Housset, Lionel Piroth, Mathilde Devaux, Gilles Pialoux, Aurelie Martin, Vincent Dubee, Jerome Frey, Audrey Le Bot, Charles Cazanave, Philippe Petua, Roland Liblau, Fabrice Carrat, Youri Yordanov
Summary: This study compared the clinical and virological outcomes in Omicron BA.1 and BA.2-infected patients who received sotrovimab and nirmatrelvir for the prevention of severe COVID-19. The results showed that early administration of nirmatrelvir was associated with faster viral clearance compared to sotrovimab, which may contribute to reducing transmission and preventing viral resistance.
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Review
Biochemistry & Molecular Biology
Adelie Gothland, Aude Jary, Philippe Grange, Valentin Leducq, Laurianne Beauvais-Remigereau, Nicolas Dupin, Anne-Genevieve Marcelin, Vincent Calvez
Summary: Reprogrammed metabolism, redox equilibrium, and ROS production play important roles in cancer development and are particularly influential in HHV-8 related diseases such as Kaposi sarcoma and primary effusion lymphoma. Primaquine diphosphate has been found to induce apoptosis in HHV-8 infected PEL cell lines through ROS production, indicating that targeting the redox balance could be a potential approach for treating HHV-8 related diseases. This review focuses on the role of ROS in cancer development and provides evidence for the importance of redox pathways in HHV-8 pathologies.
Review
Microbiology
Theophile Cocherie, Karen Zafilaza, Valentin Leducq, Stephane Marot, Vincent Calvez, Anne-Genevieve Marcelin, Eve Todesco
Summary: SARS-CoV-2 variants of concern have evolved through the accumulation of mutations in the Spike protein, which is responsible for viral binding and contains immunodominant epitopes. Different variants have emerged, each with unique characteristics in terms of transmissibility, virulence, and immune escape. The appearance of successive variants has led to the progressive improvement of SARS-CoV-2's transmissibility and its ability to evade the immune system. This review provides a comprehensive summary of the impacts of Spike mutations and the variants of concern.
Letter
Infectious Diseases
Aude Jary, Sokleaph Cheng, Stephane Marot, Gervillien Arnold Malonga, Theophile Cocherie, Steve Wignall, Vincent Calvez, Sophat Phal, Kem Vichet, Anne-Genevieve Marcelin, Gauthier Delvallez
JOURNAL OF INFECTION
(2023)
Article
Virology
Djeneba B. Fofana, Houdou Diarra, Ibrahima Guindo, Mahamadou K. Savadogo, Marceline d'Almeida, Fatoumata I. Diallo, Aliou Balde, Cathia Soulie, Amadou Kone, Anne-Genevieve Marcelin, Almoustapha I. Maiga, Sidonie Lambert-Niclot, Mamoudou Maiga, Sally McFall, Claudia A. Hawkins, Robert L. Murphy, Mariam Sylla, Christine Katlama, Jane L. Holl, Vincent Calvez, Laurence Morand-Joubert
Summary: Limited data exist on INI resistance in children living with HIV/AIDS in West Africa. A study was conducted on HIV-1-infected children in Benin and Mali, and it was found that no major INI resistance mutations were detected in INI-naive patients.
Correction
Immunology
Bernard Vanhove, Stephane Marot, Ray T. T. So, Benjamin Gaborit, Gwenaelle Evanno, Isabelle Malet, Guillaume Lafrogne, Edwige Mevel, Carine Ciron, Pierre-Joseph Royer, Elsa Lheriteau, Francois Raffi, Roberto Bruzzone, Chris Ka Pun Mok, Odile Duvaux, Anne-Genevieve Marcelin, Vincent Calvez
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Health Care Sciences & Services
Baptiste Sellem, Basma Abdi, Minh Le, Roland Tubiana, Marc-Antoine Valantin, Sophie Seang, Luminita Schneider, Antoine Faycal, Gilles Peytavin, Cathia Soulie, Anne-Genevieve Marcelin, Christine Katlama, Valerie Pourcher, Romain Palich
Summary: In this observational study, researchers evaluated the effectiveness of administering bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 5 or 4 days a week in maintaining viral suppression in people living with HIV. The study included 85 patients who started intermittent B/F/TAF between November 28, 2018, and July 30, 2020. The results showed a high success rate in terms of both virological success and strategy success, indicating that the intermittent dosing of B/F/TAF could effectively control HIV replication while reducing exposure to antiretroviral therapy (ART).
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Letter
Infectious Diseases
Elisa Teyssou, Stephane Marot, Adelie Gothland, Isabelle Malet, Karen Zafilaza, Valentin Leducq, Theophile Cocherie, Eve Todesco, Cathia Soulie, Anne-Genevieve Marcelin, Vincent Calvez
JOURNAL OF INFECTION
(2023)